A 28-year-old woman with HIV (CD4 count 85 cells/μL) presents with disseminated vesicular lesions in multiple non-contiguous dermatomes, severe pain, and fever. She has been on antiretroviral therapy for 2 months. Tzanck smear shows multinucleated giant cells. What is the most appropriate immediate management?

Explanation

## Disseminated Herpes Zoster in Severe Immunosuppression ### Clinical Context and Risk Stratification **Key Point:** A CD4 count of 85 cells/μL represents severe immunosuppression (CD4 <100) with high risk for disseminated, severe, and potentially life-threatening herpes zoster with visceral involvement (hepatitis, pneumonitis, encephalitis). **High-Yield:** Disseminated zoster (≥2 non-contiguous dermatomes) in advanced HIV requires **intravenous acyclovir**, not oral therapy, regardless of how early in the course. ### Severity Indicators Requiring IV Therapy | Feature | Risk Level | Threshold for IV Therapy | |---------|-----------|-------------------------| | CD4 count | Severe | <100 cells/μL | | Distribution | Disseminated | ≥2 non-contiguous dermatomes | | Systemic signs | Present | Fever, malaise | | Complications | High risk | Encephalitis, hepatitis, pneumonitis | | Tzanck smear | Positive | Confirms HSV/VZV | **Clinical Pearl:** In severely immunocompromised patients, oral antivirals achieve insufficient CNS and visceral penetration. Disseminated zoster can progress to post-herpetic neuralgia, bacterial superinfection, and life-threatening disseminated disease (VZV encephalitis, pneumonitis) if treated inadequately. ### Intravenous Acyclovir Dosing and Monitoring **Key Point:** Standard IV acyclovir for disseminated zoster in immunocompromised hosts: - **Dose:** 10–15 mg/kg IV every 8 hours (30–45 mg/kg/day) - **Duration:** 10–14 days or until clinical improvement - **Infusion:** Over 1 hour (rapid infusion increases nephrotoxicity and neurotoxicity risk) **Warning:** Monitor closely for: - **Nephrotoxicity:** Ensure adequate hydration; check creatinine, BUN daily - **Neurotoxicity:** Confusion, hallucinations, tremor, seizures (especially if renal impairment or elderly) - **Phlebitis:** Use central line if possible; peripheral IV causes pain and thrombophlebitis ### Transition to Oral Therapy **Clinical Pearl:** Once clinical improvement occurs (lesions stop spreading, systemic symptoms resolve), transition to oral valacyclovir 1 g TDS to complete the course, reducing hospitalization duration. ### Why Oral Therapy Is Inadequate Here **Mnemonic:** **DIVA** — Disseminated, Immunocompromised, Visceral risk, Advanced CD4 → IV Acyclovir Oral valacyclovir, despite superior bioavailability, cannot reliably prevent CNS and visceral dissemination in CD4 <100. The risk of VZV encephalitis, meningitis, and hepatitis is unacceptably high with oral-only therapy. ### Immune Reconstitution and ART **Key Point:** Ensure ART adherence; CD4 recovery is the long-term solution. Immune reconstitution inflammatory syndrome (IRIS) is rare with VZV but possible; monitor for worsening inflammation after CD4 recovery.